CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release
Jun 14, 2017
News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.
CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation
May 02, 2017
Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.
Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets
Apr 04, 2017
If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.
ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products
Mar 24, 2017
Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]
Medical Marijuana Stock CPH Plants First Seeds in $800M Brazilian Market
Mar 22, 2017
There is no doubt about it – medical marijuana stocks are lighting up the ASX right now, as the mainstream media and investment community at large is finally starting to pick up on what we have been saying for over 12 months now.
Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?
Mar 16, 2017
One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.
Strategic Cannabis Acquisition Complete: MXC Set to Break Ground in Europe, Australia the Next Step
Feb 23, 2017
In the case of MGC Pharmaceuticals (ASX: MXC), this ASX-dwelling green thumb is making a bee-line for the global medical cannabis market. This most recent move by the Australian government opens up several commercial channels for MXC with regard to its medical cannabis and cosmetics plays, given recent developments with its European operations.
CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.
A Medical Cannabis First: CPH Secures Animal Feed Product Registration
Jan 18, 2017
It has been a busy two months for Creso Pharma (ASX: CPH) since we last featured the company in November 2016 and certainly a happy new year thus far with the news that CPH recently obtained the first ever EU registration for two CBD-based animal feed nutraceutical products.
First Cannabis Revenues in Sight for CPH
Nov 07, 2016
The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.
NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks
Oct 26, 2016
Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.
Newly Listed Medical Cannabis Stock Targets $200BN Nutraceutical Opportunity
Oct 20, 2016
The low-risk health profile of medical cannabis (MC) has finally gained enough traction to allow legislation to soften… which is why many investors have raised their binoculars on the lookout for bright medical cannabis companies at an early stage of development.
Positive Phase II Results: DXB on Track to Find Kidney Disease Solution
Oct 10, 2016
There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.
MXC Expecting Imminent Medical Cannabis Revenue Deals
Oct 06, 2016
As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).